Cytogen Inc

Cytogen Inc has a market price of 5980.0 KRW and a market cap of 138,298,616,820 KRW, with a price-to-book ratio of 3.89 and a price-to-tangible-book ratio of 3.89. The company's liquidity position is characterized by a current ratio of 2.93 and cash and equivalents of 10,990,926,290 KRW, but it has a negative net cash position after subtracting total debt. The debt-to-equity ratio is 0.46, indicating a moderate level of leverage. The company's profitability is weak, with a return on equity of -0.3471 and a return on assets of -0.1983, both significantly below the industry median for Biotechnology & Medical Research. Gross profit of 5,614,992,010 KRW is a small fraction of total revenue of 26,054,851,080 KRW, and the company reported an operating loss of 11,233,152,040 KRW and a net loss of 12,342,882,570 KRW. These metrics suggest the company is not currently generating sufficient returns to justify its capital structure. Cytogen Inc's revenue is derived from liquid biopsy application services, including biomarker discovery and verification, and precision medical services. The company distributes its products domestically and to overseas markets, but the input data does not provide specific geographic revenue breakdowns or segment details. The lack of segment data limits the ability to assess geographic or product concentration risk. The company's growth trajectory is uncertain, as the input data does not provide forward-looking revenue guidance or historical growth rates. The operating cash flow of -6,954,150,410 KRW and free cash flow of -11,203,091,990 KRW indicate the company is not generating positive cash from operations and is likely relying on external financing to fund operations. The capital expenditure of -2,037,770,600 KRW suggests the company is investing in its operations, but the negative sign indicates it is a cash outflow. The risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity challenges. The company's dilution risk is low, but the negative net cash position suggests potential pressure to raise additional capital, which could lead to future dilution. The company's financial structure and negative cash flows increase the likelihood of future capital-raising activities. Recent events and filings are not detailed in the input data, so no specific recent developments can be cited. The company's financial performance and risk profile suggest it is in a development phase, with significant financial challenges that may require strategic adjustments or additional capital to address.